Please try another search
For the fiscal year ended 31 March 2022, BrightPath Biotherapeutics Co Ltd revenues increased from Y2.5M to Y15.4M. Net loss decreased 14% to Y1.48B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Share issuance cost decrease of 76% to Y2.2M (expense), Impairment loss decrease of 41% to Y5.7M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 15.08 | 0.07 | 0.05 | 0.21 |
Gross Profit | 11.84 | 0.05 | 0.04 | 0.16 |
Operating Income | -401.31 | -353.84 | -319.67 | -401.05 |
Net Income | -405.52 | -354.75 | -320.93 | -402.99 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 2771.2 | 2860.23 | 3202.72 | 3319.55 |
Total Liabilities | 239.73 | 175.03 | 164.77 | 170.63 |
Total Equity | 2531.47 | 2685.2 | 3037.95 | 3148.92 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 12 Months | 0 Months | 6 Months | 0 Months |
Cash From Operating Activities | -1512.02 | -751.93 | ||
Cash From Investing Activities | -17.57 | -11.29 | ||
Cash From Financing Activities | 569.23 | 228.68 | ||
Net Change in Cash | -960.36 | -534.54 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review